141 related articles for article (PubMed ID: 29749339)
1. Intestinal perforation after regorafenib usage.
Sarıcı B; Karakaş S; Uylas U; Aktaş A; Dikilitaş M; Kayaalp C
Turk J Gastroenterol; 2018 Mar; 29(2):245-247. PubMed ID: 29749339
[No Abstract] [Full Text] [Related]
2. Regorafenib use as a possible cause of intestinal perforation.
Adenis A; Kotecki N; Decanter G; Clisant S; Penel N
Acta Oncol; 2013 Nov; 52(8):1789-90. PubMed ID: 24024697
[No Abstract] [Full Text] [Related]
3. Gastrointestinal perforation during regorafenib administration in a case with hepatic metastases of colon cancer.
Ogata K; Takamori H; Umezaki N; Yagi T; Ogawa K; Ozaki N; Hayashi H; Tanaka H; Ikuta Y; Doi K
J Chemother; 2017 Oct; 29(5):314-316. PubMed ID: 27438692
[TBL] [Abstract][Full Text] [Related]
4. Intestinal Perforation in a Patient with Colon Cancer during Treatment with Regorafenib: A Case Report and Review of the Literature.
Ouchi R; Okada K; Usui K; Kurata N; Suzuki S; Nagao M; Watanabe Y; Koyama K
Tohoku J Exp Med; 2021 Jul; 254(3):207-211. PubMed ID: 34321384
[TBL] [Abstract][Full Text] [Related]
5. Colon perforation during sorafenib therapy for advanced hepatocelluar carcinoma. A case report.
Park SG; Chung CH; Park CY
Tumori; 2011; 97(6):794-9. PubMed ID: 22322848
[TBL] [Abstract][Full Text] [Related]
6. Regorafenib Also Can Cause Osteonecrosis of the Jaw.
Antonuzzo L; Lunghi A; Giommoni E; Brugia M; Di Costanzo F
J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26857267
[No Abstract] [Full Text] [Related]
7. [A case of erythema multiforme induced by regorafenib therapy for metastatic colon cancer].
Mii Y; Fukuoka E; Murata K; Otsubo D; Sawa H; Oka S; Iwatani Y; Kuroda D
Gan To Kagaku Ryoho; 2014 Nov; 41(12):1841-3. PubMed ID: 25731348
[TBL] [Abstract][Full Text] [Related]
8. Regorafenib-Associated Vulvar Psoriasiform Skin Reaction: Case of the Month from the ISSVD Case Consultation Committee.
Bourne EL; Day T; Scurry J
J Low Genit Tract Dis; 2016 Jul; 20(3):e44-5. PubMed ID: 27195780
[No Abstract] [Full Text] [Related]
9. Regorafenib (Stivarga) and gastrointestinal stromal tumours after treatment failure. Radiological improvement but major adverse effects.
Prescrire Int; 2015 Oct; 24(164):234. PubMed ID: 26594725
[TBL] [Abstract][Full Text] [Related]
10. Regorafenib-Associated Fatigue: A Systematic Review and Meta-analysis.
Invally M; Kanukula R; Salam MA; Shruthi G
Am J Ther; 2018; 25(6):e715-e717. PubMed ID: 29465445
[No Abstract] [Full Text] [Related]
11. Ileal perforation following cetuximab and FOLFIRI chemotherapy in a patient with ascending colon cancer with peritoneal carcinomatosis.
Kim YW
J BUON; 2017; 22(3):804-805. PubMed ID: 28730797
[No Abstract] [Full Text] [Related]
12. Severe Maculopapular Exanthema Induced by Regorafenib: Successful Desensitization and Adaptation of a Dosage Regimen.
García-Gutiérrez I; Acevedo M; Tornero P; Matilla A; Márquez L; Sánchez-Herrero A; Prieto-García A
J Investig Allergol Clin Immunol; 2019 Aug; 29(4):300-302. PubMed ID: 31478526
[No Abstract] [Full Text] [Related]
13. Multiple colon ulcerations, perforation and death during treatment of malignant melanoma with sorafenib.
Frieling T; Heise J; Wassilew SW
Dtsch Med Wochenschr; 2009 Jul; 134(28-29):e1-2, 1464-6. PubMed ID: 19572243
[TBL] [Abstract][Full Text] [Related]
14. Regorafenib- associated panniculitis.
Chockalingam R; Aung P; Patel AB
Dermatol Online J; 2016 Jun; 22(6):. PubMed ID: 27617607
[TBL] [Abstract][Full Text] [Related]
15. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study.
Bekaii-Saab TS; Ou FS; Ahn DH; Boland PM; Ciombor KK; Heying EN; Dockter TJ; Jacobs NL; Pasche BC; Cleary JM; Meyers JP; Desnoyers RJ; McCune JS; Pedersen K; Barzi A; Chiorean EG; Sloan J; Lacouture ME; Lenz HJ; Grothey A
Lancet Oncol; 2019 Aug; 20(8):1070-1082. PubMed ID: 31262657
[TBL] [Abstract][Full Text] [Related]
16. Regorafenib for treatment of hepatocellular carcinoma.
Sherman M
Hepatology; 2018 Mar; 67(3):1162-1165. PubMed ID: 29059458
[No Abstract] [Full Text] [Related]
17. Regorafenib in metastatic colorectal cancer: optimal dosing and patient selection recommendations.
Grothey A
Clin Adv Hematol Oncol; 2015 Aug; 13(8):514-7. PubMed ID: 26351814
[No Abstract] [Full Text] [Related]
18. Regorafenib for Metastatic Colorectal Cancer: Common Toxicities and Prevention Strategies.
Draper A
Oncology (Williston Park); 2019 Apr; 33(4):126-7. PubMed ID: 30990563
[No Abstract] [Full Text] [Related]
19. Regorafenib: start low and go slow.
Tabchi S; Ghosn M
Target Oncol; 2015 Sep; 10(3):445-7. PubMed ID: 25548130
[No Abstract] [Full Text] [Related]
20. Cardiovascular toxicity of regorafenib for heavily-treated osteosarcoma.
Saito Y; Makimoto A; Miura M; Yuza Y
Pediatr Int; 2021 Jul; 63(7):857-859. PubMed ID: 33277804
[No Abstract] [Full Text] [Related]
[Next] [New Search]
